Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection

Inclusion Criteria: * Diagnosis of chronic hepatitis C genotype 1 infection * BMI 18 and 38 kg/m2 * Null responder to pegylated interferon alpha and ribavirin Exclusion Criteria: * Co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) * Significant liver disease in addition to hepatitis C * Decompensated liver disease medical history or current clinical features * Histologic evidence of hepatic cirrhosis * Concurrent clinically significant medical diagnosis (other than CHC) * Concurrent social conditions (e.g. drugs of abuse, alcohol excess, poor living accommodation) * Clinically significant illness within 30 days preceding entry into the study * Participated in an investigational drug study within 30 days or 5 half-lives, whichever is longer, prior to the start of study medication * History of clinically significant allergic drug reactions